7月25日，创新药企维立志博-B（09887.HK）在港交所主板挂牌上市，盘中大涨115.71%，引发市场广泛关注。该公司此前公开发售部分获3494.78倍超额认购，最终以每股35港元的上限价格定价，募集资金净额约11.79亿港元。
维立志博是一家专注于肿瘤免疫疗法的临床阶段生物科技公司，致力于开发突破性癌症疗法。公司拥有14款候选药物，涵盖TCE、IO 2.0和ADC三大领域，其中6款已进入临床阶段。投资者对公司的创新技术平台和差异化产品管线表现出强烈兴趣，多家知名机构参与基石投资，包括正心谷资本、高毅资产、腾讯等。
尽管维立志博上市首日表现亮眼，但作为尚未盈利的生物科技公司，其未来发展仍面临研发风险、激烈的市场竞争以及商业化挑战。投资者需密切关注公司核心产品的临床进展及后续产品管线的拓展情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.